Oculis Holding AG Ordinary shares - Asset Resilience Ratio
Oculis Holding AG Ordinary shares (OCS) has an Asset Resilience Ratio of 55.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Oculis Holding AG Ordinary shares's Asset Resilience Ratio has changed over time. Check Oculis Holding AG Ordinary shares strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Oculis Holding AG Ordinary shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oculis Holding AG Ordinary shares stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $131.83 Million | 55.81% |
| Total Liquid Assets | $131.83 Million | 55.81% |
Asset Resilience Insights
- Very High Liquidity: Oculis Holding AG Ordinary shares maintains exceptional liquid asset reserves at 55.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oculis Holding AG Ordinary shares Industry Peers by Asset Resilience Ratio
Compare Oculis Holding AG Ordinary shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Oculis Holding AG Ordinary shares (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Oculis Holding AG Ordinary shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.81% | $131.83 Million | $236.23 Million | -3.15pp |
| 2024-12-31 | 58.96% | $70.95 Million | $120.35 Million | +12.32pp |
| 2023-12-31 | 46.63% | $53.32 Million | $114.35 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $37.06 Million | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more